RT Journal Article
SR Electronic
T1 Post-covid medical complaints after SARS-CoV-2 Omicron vs Delta variants - a prospective cohort study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.05.23.22275445
DO 10.1101/2022.05.23.22275445
A1 Magnusson, Karin
A1 Kristoffersen, Doris Tove
A1 Dell’Isola, Andrea
A1 Kiadaliri, Ali
A1 Turkiewicz, Aleksandra
A1 Runhaar, Jos
A1 Bierma-Zeinstra, Sita
A1 Englund, Martin
A1 Magnus, Per Minor
A1 Kinge, Jonas Minet
YR 2022
UL http://medrxiv.org/content/early/2022/05/25/2022.05.23.22275445.abstract
AB Objective To examine whether persons infected with the SARS-CoV-2 omicron variant have an altered risk of post-covid complaints and healthcare use when compared to 1) persons testing negative, and 2) persons with delta.Design Prospective cohort study with 126 days follow-up and a time-to-event approach.Setting A registry-based study including Norwegian residents.Participants All persons aged 18-70 years living in Norway and who had a negative polymerase chain reaction (PCR) test for SARS-CoV-2 (N=105 196, mean (SD) age 42 (14), 50% women)) or positive test with confirmed omicron variant (N=13 028, mean (SD) age 37 (13), 50% women) or delta variant (N=23 368, mean (SD) age 40 (12), 50% women) in December 2021. Individuals with hospital contacts or non-screened PCR test were excluded.Main outcome measures Symptoms/complaints and diagnosis of musculoskeletal pain, fatigue, cough, heart palpitations, shortness of breath, anxiety/depression and brain fog at the general practitioner or emergency ward as recorded in national registries and as observed for the whole follow-up period as well as in periods 14-30 days, 30-90 days and 90 days or more.Results Persons with omicron or delta had similarly increased risk of post-covid fatigue compared to persons testing negative, with a hazard ratio (HR)=1.21 (CI:1.10-1.33) for omicron and HR=1.26 (CI: 1.17-1.35) for delta, for up to 126 days after the test date. They also had an increased risk of shortness of breath (HR=1.43, CI, 1.14-1.80 and HR=1.70, CI, 1.46-1.98 for omicron and delta, respectively, relative to negative). Omicron was related with a similar, and no increased risk of musculoskeletal pain, cough, heart palpitations, anxiety/depression when compared to delta and when compared to test negative. The risk of complaints was similar for omicron and delta and decreased over time for the post-covid periods 14-30 days, 30-90 days and 90 days or more.Conclusions SARS-CoV-2 omicron and delta infection are associated with similarly increased risks of post-covid complaints when compared to non-infected. The omicron variant will likely lead to a temporarily increased burden on healthcare services.Competing Interest StatementWe declare no conflicts of interest, except for Dr. Englund reporting grants from The Swedish Research Council, grants from Osterlund Foundation, grants from Governmental Funding of Clinical Research within National Health Service (ALF), grants from Greta and Johan Kock Foundations, grants from The Swedish Rheumatism Association, during the conduct of the study.Funding StatementThis study was supported by the Foundation for Research in Rheumatology (FOREUM), and by the Norwegian Institute of Public Health (internal funding). The funding sources had no influence on the design or conduct of the study; collection, management, analysis, nor the interpretation of the data; preparation, review, or approval of the manuscript; nor the decision to submit the manuscript for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional board review was conducted, and The Ethics Committee of South-East Norway confirmed (June 4th 2020, #153204) that external ethical board review was not required.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe study method and statistical analyses are all described in detail in the Methods chapter and throughout the paper. Individual-level data of patients included in this paper after de-identification are considered sensitive and will not be shared. However, the individual-level data in the registries compiled in Beredt C19 are accessible to authorized researchers after ethical approval and application to "helsedata.no/en" administered by the Norwegian Directorate of eHealth. Data requests may be sent to "service@helsedata.no.